Status:
RECRUITING
Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Sickle Cell Disease (SCD)
Eligibility:
All Genders
18+ years
Brief Summary
Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets...
Detailed Description
Sickle cell disease is the most common inherited blood disorder worldwide. It is a hemoglobinopathy characterized by a chronic hemolysis, vaso-occlusion, endotheliopathy, coagulation activation and ch...
Eligibility Criteria
Inclusion
- Sickle cell disease SS or S-béta° thalassemia
- Patient at steady state since at least 1 year or at steady state (without crisis), or during vaso-occlusive crisis or during acute chest syndrome
- Age \> 18 years old
Exclusion
- Patient objects to take part in the study Hematologic disorder (leukemia, myeloma, myelodysplasic syndrome, myeloproliferative syndrome)
- Immune thrombocytopenia, Immunosuppressive or anti-inflammatory (biotherapies, corticosteroids, non steroidal anti-inflammatories drugs) Page 12 sur 23
- Anti-platelets agents
- Red blood cell exchange or transfusion \< 3 months
Key Trial Info
Start Date :
March 13 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2028
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06887907
Start Date
March 13 2025
End Date
April 1 2028
Last Update
March 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Toulouse
Toulouse, France, France, 31059